4. Süddeutsches Peritonealdialyse-Seminar – Peritonealdialyse-Update mit breitem Themenspektrum

Das Süddeutsche Peritonealdialyse-Seminar, welches am 2. März erneut unter der Leitung von Prof. Dr. Vedat Schwenger, Heidelberg, sowie Prof. Dr. Mark Dominik Alscher, Stuttgart, und mit Unterstützung der Fresenius Medical Care GmbH im Universitätsklinikum Heidelberg stattfand, hat sich inzwischen zu einer der bedeutendsten Fortbildungsveranstaltungen im Bereich Peritonealdialyse (PD) in Deutschland entwickelt. Namhafte Referenten gaben ein umfassendes Update zu allen wesentlichen Aspekten der PD. Dabei wurden neben den klassischen PD-Fragestellungen auch angrenzende Themen mit hoher Relevanz für den klinischen Alltag diskutiert. Darüber hinaus reflektierte das Programm auch betriebs- und volkswirtschaftliche Aspekte der Bauchfelldialyse. Die zahlreichen Teilnehmer nutzen diese tradierte und hochwertige PD-Fortbildung zum Erfahrungsaustausch sowie zum Erwerb aktuellen Wissens und der Diskussion neuer Aspekte.

• Literatur

• 1 Wizemann V, Wabel P, Chamney P et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 1574-1579
• 2 Wabel P, Moissl U, Chamney P et al. Towards improved cardiovascular management: the necessity of combining blood pressure and fluid overload. Nephrol Dial Transplant 2008; 23: 2965-2971
• 3 Termorshuizen F, Dekker FW, van Manen JG et al. NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004; 15: 1061-1070
• 4 Fischbach M, Warady BA. Peritoneal dialysis prescription in children: bedside principles for optimal practice. Pediatr Nephrol 2009; 24: 1633-1642
• 5 Tattersall J, Dekker F, Heimbürger O et al. ERBP Advisory Board. When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. Nephrol Dial Transplant 2011; 26: 2082-2086
• 6 Lassalle M, Labeeuw M, Frimat L, Ursea N. Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival. Kidney Int 2010; 77: 700-707
• 7 Goldfarb-Rumyantzev AZ, Hurdle JF, Scandling JD et al. The role of pretransplantation renal replacement therapy modality in kidney allograft and recipient survival. Am J Kidney Dis 2005; 46: 537-549
• 8 Schwenger V, Döhler B, Morath C et al. The role of pretransplant dialysis modality on renal allograft outcome. Nephrol Dial Transplant 2011; 26: 3761-3766
• 9 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1996
• 10 Kim S, Oh KH, Oh J et al. Biocompatible peritoneal dialysis solution preserves residual renal function. Am J Nephrol 2012; 36: 305-316
• 11 Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248-255
• 12 Lee HY, Choi HY, Park HC et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21: 2893-2899
• 13 Montenegro J, Saracho R, Gallardo I et al. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 2007; 22: 1703-1708
• 14 Johnson DW, Brown FG, Clarke M et al. balANZ Trial Investigators. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23: 1097-1107
• 15 Johnson DW, Brown FG, Clarke M. balANZ Trial Investigators et al. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrol Dial Transplant 2012; 27: 4445-4453
• 16 Diemont WL, Vruggink PA, Meuleman EJ et al. Sexual dysfunction after renal replacement therapy. Am J Kidney Dis 2000; 35: 845-851
• 17 Pisoni RL, Wikström B, Elder SJ et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006; 21: 3495-3505
• 18 Masuda T, Murata M, Honma S et al. Sleep-disordered breathing predicts cardiovascular events and mortality in hemodialysis patients. Nephrol Dial Transplant 2011; 26: 2289-2295
• 19 Tang SC, Lam B, Yao TJ et al. Sleep apnea is a novel risk predictor of cardiovascular morbidity and death in patients receiving peritoneal dialysis. Kidney Int 2010; 77: 1031-1038
• 20 Bart BA, Goldsmith SR, Lee KL et al. Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296-2304